Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition affecting around 8.3% of adults. This treatment provides rapid relief from ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

The Food and Drug Administration (FDA) recently gave approval for clinical trials in the U.S. of a COVID-19 nasal vaccine ...

The newly FDA-approved nasal spray called Spravato is being manufactured by Johnson & Johnson's and is a standalone treatment for major depressive disorder.

Mumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food ...

Lupin receives US FDA approval for generic Atrovent nasal spray, 0.06%: Our Bureau,Mumbai Tuesday, January 28, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) anno ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University ... A version of the vaccine has been available in India since 2022 through a licensing agreement between WashU ...

New licensing rules mandate compliance with Schedule TB for ASU nasal sprays for patient safety: Shardul Nautiyal, Mumbai Friday, January 24, 2025, 08:00 Hrs [IST] The Union minis ...

KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...